GlobeNewswire Inc | Jan 10, 2022 07:00AM EST

January 10, 2022

WARREN, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (Bellerophon or the Company), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that Naseem Amin, M.D., Chairman of Bellerophons Board of Directors, will present a corporate overview at the H.C. Wainwright BioConnect 2022 Conference, being held virtually January 10-13, 2022.

The Companys presentation will be available on-demand beginning at 7:00 AM Eastern Time on Monday, January 10, 2022, in the Investors section on the Companys website at www.bellerophon.com.

About BellerophonBellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing multiple product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery system. For more information, please visit www.bellerophon.com.

ContactsLifeSci Advisors:Brian Ritchie(212) 915-2578britchie@lifesciadvisors.com